Pieris Pharmaceuticals Inc
NASDAQ:PIRS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
|
US |
|
Keramika Indonesia Assosiasi Tbk PT
IDX:KIAS
|
ID |
Income Statement
Earnings Waterfall
Pieris Pharmaceuticals Inc
Income Statement
Pieris Pharmaceuticals Inc
| Dec-2014 | Mar-2015 | Jun-2015 | Sep-2015 | Dec-2015 | Mar-2016 | Jun-2016 | Sep-2016 | Dec-2016 | Mar-2017 | Jun-2017 | Sep-2017 | Dec-2017 | Mar-2018 | Jun-2018 | Sep-2018 | Dec-2018 | Mar-2019 | Jun-2019 | Sep-2019 | Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||||||||||||||||||||
| Revenue |
5
N/A
|
4
-22%
|
4
-13%
|
4
+11%
|
3
-28%
|
4
+35%
|
5
+23%
|
5
+8%
|
6
+11%
|
6
+2%
|
7
+13%
|
10
+47%
|
25
+157%
|
28
+11%
|
38
+35%
|
42
+12%
|
29
-31%
|
33
+15%
|
27
-19%
|
34
+25%
|
46
+36%
|
51
+10%
|
57
+12%
|
45
-21%
|
29
-34%
|
32
+8%
|
24
-25%
|
25
+5%
|
31
+26%
|
27
-15%
|
27
+2%
|
28
+5%
|
26
-9%
|
17
-35%
|
33
+97%
|
47
+43%
|
43
-10%
|
41
-4%
|
21
-49%
|
1
-94%
|
|
| Operating Income | |||||||||||||||||||||||||||||||||||||||||
| Operating Expenses |
(13)
|
(14)
|
(15)
|
(17)
|
(17)
|
(18)
|
(21)
|
(24)
|
(29)
|
(32)
|
(35)
|
(37)
|
(40)
|
(43)
|
(47)
|
(54)
|
(60)
|
(67)
|
(71)
|
(72)
|
(73)
|
(71)
|
(70)
|
(68)
|
(63)
|
(67)
|
(71)
|
(78)
|
(83)
|
(81)
|
(77)
|
(71)
|
(69)
|
(62)
|
(65)
|
(69)
|
(59)
|
(60)
|
(47)
|
(19)
|
|
| Selling, General & Administrative |
(7)
|
(9)
|
(8)
|
(9)
|
(8)
|
(8)
|
(8)
|
(8)
|
(9)
|
(11)
|
(13)
|
(13)
|
(18)
|
(18)
|
(18)
|
(20)
|
(18)
|
(19)
|
(18)
|
(19)
|
(18)
|
(18)
|
(18)
|
(18)
|
(17)
|
(16)
|
(16)
|
(16)
|
(17)
|
(17)
|
(17)
|
(16)
|
(16)
|
(16)
|
(16)
|
(19)
|
(17)
|
(17)
|
(17)
|
(13)
|
|
| Research & Development |
(6)
|
(6)
|
(7)
|
(8)
|
(8)
|
(10)
|
(13)
|
(16)
|
(20)
|
(21)
|
(22)
|
(24)
|
(22)
|
(25)
|
(29)
|
(34)
|
(41)
|
(48)
|
(52)
|
(54)
|
(55)
|
(53)
|
(51)
|
(50)
|
(47)
|
(50)
|
(55)
|
(62)
|
(67)
|
(64)
|
(60)
|
(55)
|
(53)
|
(52)
|
(55)
|
(51)
|
(42)
|
(30)
|
(16)
|
(6)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
6
|
5
|
0
|
0
|
(14)
|
(14)
|
0
|
|
| Operating Income |
(7)
N/A
|
(10)
-42%
|
(11)
-7%
|
(13)
-19%
|
(14)
-5%
|
(14)
-5%
|
(17)
-16%
|
(19)
-14%
|
(23)
-20%
|
(26)
-16%
|
(28)
-8%
|
(27)
+3%
|
(15)
+47%
|
(15)
-1%
|
(9)
+38%
|
(12)
-29%
|
(31)
-164%
|
(33)
-8%
|
(43)
-30%
|
(38)
+11%
|
(27)
+29%
|
(20)
+25%
|
(13)
+37%
|
(23)
-79%
|
(34)
-49%
|
(35)
-4%
|
(47)
-34%
|
(53)
-13%
|
(52)
+3%
|
(54)
-5%
|
(50)
+8%
|
(43)
+14%
|
(43)
-1%
|
(45)
-5%
|
(32)
+29%
|
(22)
+32%
|
(16)
+28%
|
(20)
-23%
|
(26)
-32%
|
(18)
+30%
|
|
| Pre-Tax Income | |||||||||||||||||||||||||||||||||||||||||
| Interest Income Expense |
(3)
|
(3)
|
(2)
|
(2)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
1
|
1
|
1
|
2
|
2
|
2
|
1
|
1
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
3
|
4
|
6
|
6
|
6
|
8
|
0
|
0
|
(12)
|
(14)
|
0
|
0
|
1
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(1)
|
(3)
|
(2)
|
(3)
|
(0)
|
2
|
2
|
3
|
1
|
0
|
(0)
|
0
|
(0)
|
(2)
|
(4)
|
(3)
|
(2)
|
0
|
2
|
2
|
2
|
2
|
1
|
3
|
4
|
4
|
3
|
2
|
1
|
0
|
|
| Pre-Tax Income |
(10)
N/A
|
(13)
-30%
|
(13)
-5%
|
(15)
-14%
|
(14)
+9%
|
(14)
-3%
|
(17)
-16%
|
(19)
-14%
|
(23)
-19%
|
(26)
-17%
|
(30)
-13%
|
(31)
-2%
|
(17)
+46%
|
(17)
-4%
|
(8)
+52%
|
(8)
+9%
|
(27)
-257%
|
(29)
-6%
|
(40)
-40%
|
(37)
+9%
|
(25)
+30%
|
(19)
+27%
|
(12)
+36%
|
(24)
-98%
|
(37)
-57%
|
(38)
-2%
|
(48)
-28%
|
(50)
-5%
|
(46)
+9%
|
(47)
-2%
|
(42)
+11%
|
(35)
+16%
|
(33)
+4%
|
(41)
-24%
|
(27)
+35%
|
(28)
-4%
|
(25)
+13%
|
(16)
+34%
|
(24)
-47%
|
(16)
+33%
|
|
| Net Income | |||||||||||||||||||||||||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(10)
|
(13)
|
(13)
|
(15)
|
(14)
|
(15)
|
(17)
|
(19)
|
(23)
|
(27)
|
(31)
|
(32)
|
(18)
|
(18)
|
(8)
|
(8)
|
(27)
|
(28)
|
(40)
|
(36)
|
(25)
|
(19)
|
(12)
|
(24)
|
(37)
|
(38)
|
(48)
|
(51)
|
(46)
|
(47)
|
(42)
|
(35)
|
(33)
|
(41)
|
(27)
|
(28)
|
(25)
|
(16)
|
(24)
|
(16)
|
|
| Net Income (Common) |
(10)
N/A
|
(13)
-30%
|
(13)
-5%
|
(15)
-14%
|
(14)
+8%
|
(15)
-3%
|
(17)
-16%
|
(19)
-13%
|
(23)
-19%
|
(27)
-17%
|
(31)
-16%
|
(32)
-3%
|
(18)
+44%
|
(18)
-4%
|
(8)
+54%
|
(8)
+11%
|
(27)
-253%
|
(28)
-6%
|
(40)
-41%
|
(36)
+9%
|
(28)
+22%
|
(22)
+24%
|
(15)
+32%
|
(26)
-79%
|
(37)
-41%
|
(38)
-2%
|
(48)
-28%
|
(51)
-5%
|
(46)
+10%
|
(47)
-2%
|
(42)
+11%
|
(35)
+16%
|
(33)
+4%
|
(41)
-24%
|
(27)
+35%
|
(28)
-4%
|
(25)
+13%
|
(16)
+34%
|
(24)
-47%
|
(16)
+33%
|
|
| EPS (Diluted) |
-26.91
N/A
|
-34.71
-29%
|
-36.47
-5%
|
-31.52
+14%
|
-32.7
-4%
|
-29.14
+11%
|
-33
-13%
|
-35.57
-8%
|
-43.76
-23%
|
-49.5
-13%
|
-56.78
-15%
|
-57.11
-1%
|
-32.14
+44%
|
-29.34
+9%
|
-12.57
+57%
|
-11.21
+11%
|
-40.29
-259%
|
-44.63
-11%
|
-64.94
-46%
|
-58.96
+9%
|
-44.72
+24%
|
-31.22
+30%
|
-22.5
+28%
|
-38.92
-73%
|
-54.67
-40%
|
-53.7
+2%
|
-62.47
-16%
|
-59.74
+4%
|
-56.69
+5%
|
-50.66
+11%
|
-44.77
+12%
|
-37.31
+17%
|
-35.89
+4%
|
-44.42
-24%
|
-24.63
+45%
|
-22.7
+8%
|
-21.8
+4%
|
-13.13
+40%
|
-18.33
-40%
|
-12.08
+34%
|
|